NCT02477709 is a Phase 2 clinical trial of Gefapixant in Idiopathic Pulmonary Fibrosis, sponsored by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

What drugs are being tested in NCT02477709?

Interventions in NCT02477709: Gefapixant.

What condition does NCT02477709 study?

NCT02477709 studies Idiopathic Pulmonary Fibrosis.

Is NCT02477709 still recruiting?

NCT02477709 is currently completed. Last updated 25 June 2019.

Are results published for NCT02477709?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-06-25 · How we verify

NCT02477709

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Completed Phase 2 Results posted Last updated 25 June 2019

What this trial tests

Phase 2 trial testing Gefapixant in Idiopathic Pulmonary Fibrosis in 6 participants. Completed in 21 August 2015.

Timeline

20 July 2015

Primary endpoint
7 August 2015

21 August 2015

Quick facts

Lead sponsor	Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	20 July 2015
Primary completion	7 August 2015
Estimated completion	21 August 2015
Sites	1 location across United States

Drugs / interventions tested

Gefapixant — full drug profile →

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full company profile →

Who can join

40 and older, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Effect of Gefapixant on BP Primary · 6 hours

BP data will be summarized using descriptive statistics

Mean Systolic BP at 6 hrs

Group	Value	95% CI
Gefapixant	122	90 – 142

Mean Diastolic BP at 6 hrs

Group	Value	95% CI
Gefapixant	76	56 – 96

Adverse events — posted to ClinicalTrials.gov

Time frame: 2 weeks. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Gefapixant

Serious: 0/6 (0%)

Deaths: —

Other adverse events (9 terms — click to expand)

Reaction	System	Gefapixant
Hypogeusia	Nervous system disorders	—
Dysgeusia	Nervous system disorders	—
Decreased Appetite	Metabolism and nutrition disorders	—
Pain	General disorders	—
Feeling Hot	General disorders	—
Arthralgia	Musculoskeletal and connective tissue disorders	—
Local Swelling	General disorders	—
Asthenia	General disorders	—
Vision Blurred	Eye disorders	—

Data from ClinicalTrials.gov NCT02477709 adverse events section.

Sponsor's own description

This study assesses the tolerability of a single dose of gefapixant (AF-219) in participants with idiopathic pulmonary fibrosis (IPF). Six eligible participants will receive a single 150 mg dose of gefapixant and undergo tolerability and PK assessments.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Ion channels as therapeutic antibody targets.
Hutchings CJ, Colussi P, Clark TG. · · 2019 · cited 89× · PMID 30526315 · DOI 10.1080/19420862.2018.1548232
Purinergic Signaling in Endometriosis-Associated Pain.
Trapero C, Martín-Satué M. · · 2020 · cited 18× · PMID 33198179 · DOI 10.3390/ijms21228512
P2X Receptors: Potential Therapeutic Targets for Symptoms Associated With Lung Cancer - A Mini Review.
Mai Y, Guo Z, Yin W, Zhong N, et al · · 2021 · cited 17× · PMID 34268121 · DOI 10.3389/fonc.2021.691956
The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.
Han S, Suzuki-Kerr H, Vlajkovic SM, Thorne PR. · · 2022 · cited 9× · PMID 36173587 · DOI 10.1007/s11302-022-09896-w

Verify or expand the search:

Other trials of Gefapixant

Trials testing the same drug.

NCT05813223 — Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough · EARLY_PHASE1 · recruiting
NCT04193202 — Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043) · Phase 3 · completed
NCT04193176 — Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042) · Phase 3 · completed
NCT03882801 — Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039) · Phase 1 · completed
NCT03696108 — A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038 · Phase 3 · completed

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Other Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials

Trials by the same sponsor.

NCT02790840 — A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations · Phase 1 · completed
NCT02612623 — An 8-Week Refractory Chronic Cough Study (MK-7264-021) · Phase 2 · completed
NCT02612610 — A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) · Phase 2 · completed
NCT02476890 — Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014 · Phase 2 · completed
NCT02502097 — A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (M · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02477709 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last refreshed: 25 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02477709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing